Prem Watsa
Fairfax Financial Holdings
Prem Watsa Pfizer Inc stake
total: 291
Fairfax Financial Holdings PFE trades
- Total transactions:
- 10
- New positions:
- 2
- Sold out:
- 1
- Added:
- 6
- Reduced:
- 1
- Held since:
- 2020 Q4
- Held for:
- 23 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Prem Watsa holds 1,043,900 Pfizer Inc (PFE) shares with a market value of roughly $25.12M accounting for 0.95% of the overall portfolio. Fairfax Financial Holdings has held PFE since at least 2013 Q2 with 235,000 shares in our earliest available record. Prem Watsa later completely sold out the position and invested in Pfizer Inc again in 2020 Q4. Since at least 2013 Q2, Fairfax Financial Holdings has made 9 more transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $31.20
Prem Watsa's historical trades in Pfizer Inc
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.95%
|
1,043,900
|
$24.06
|
$25,116,234
|
+5.35% (+53,000)
|
+0.05%
|
|
2026 Q1
|
1.43%
|
990,900
|
$28.07
|
$27,814,563
|
+11.22% (+100,000)
|
+0.14%
|
|
2025 Q3
|
1.10%
|
890,900
|
$25.47
|
$22,691,223
|
+36.87% (+240,000)
|
+0.3%
|
|
2024 Q4
|
1.11%
|
650,900
|
$26.54
|
$17,274,886
|
+41.22% (+190,000)
|
+0.32%
|
|
2022 Q3
|
0.52%
|
460,900
|
$43.84
|
$20,206,000
|
+14.97% (+60,000)
|
+0.07%
|
|
2021 Q1
|
0.51%
|
400,900
|
$36.23
|
$14,525,000
|
+33.23% (+100,000)
|
+0.13%
|
|
2020 Q4
|
0.49%
|
$36.81
|
new
|
|||
|
2018 Q1
|
0.00%
|
$36.25
|
-100% (-210,000)
|
|||
|
2015 Q4
|
0.55%
|
$32.27
|
-10.64% (-25,000)
|
|||
|
2013 Q2
|
0.27%
|
$28.05
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.